Compare Stocks: ORGO, KMDA, AVTE, and PRTA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$15.87 -4.1%	$15.51	$89.95 ▼ $99.05	$459.99M	0.95	53,591 shs	880,376 shs
KMDA Kamada	$8.09 -0.5%	$8.05	$6.59 ▼ $9.35	$465.26M	0.9	83,171 shs	94,468 shs
ORGO Organogenesis	$0.81 -16.1%	$1.20	$0.73 ▼ $6.32	$105.15M	1.48	1.01 million shs	686,354 shs
PRTA Prothena	$8.16 -0.9%	$8.57	$7.73 ▼ $11.80	$419.02M	-0.2	507,242 shs	340,448 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+0.85%	+9.97%	+18.14%	-30.53%	+68.78%
KMDA Kamada	0.00%	+18.34%	+5.72%	+7.26%	+11.68%
ORGO Organogenesis	-8.10%	+14.89%	-20.25%	-46.09%	-85.11%
PRTA Prothena	-5.73%	+4.31%	-1.56%	-7.11%	-24.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$15.87 -4.1%	$15.51	$89.95 ▼ $99.05	$459.99M	0.95	53,591 shs	880,376 shs
KMDA Kamada	$8.09 -0.5%	$8.05	$6.59 ▼ $9.35	$465.26M	0.9	83,171 shs	94,468 shs
ORGO Organogenesis	$0.81 -16.1%	$1.20	$0.73 ▼ $6.32	$105.15M	1.48	1.01 million shs	686,354 shs
PRTA Prothena	$8.16 -0.9%	$8.57	$7.73 ▼ $11.80	$419.02M	-0.2	507,242 shs	340,448 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+0.85%	+9.97%	+18.14%	-30.53%	+68.78%
KMDA Kamada	0.00%	+18.34%	+5.72%	+7.26%	+11.68%
ORGO Organogenesis	-8.10%	+14.89%	-20.25%	-46.09%	-85.11%
PRTA Prothena	-5.73%	+4.31%	-1.56%	-7.11%	-24.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
KMDA Kamada	3.00	Buy	$13.75	70.60% Upside
ORGO Organogenesis	1.67	Reduce	$4.33	434.98% Upside
PRTA Prothena	2.86	Moderate Buy	$20.00	144.35% Upside

Current Analyst Ratings Breakdown

Latest ORGO, KMDA, AVTE, and PRTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/9/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B) ➝ Buy (B-)
11/9/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
11/9/2026	KMDA Kamada	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$12.00
11/6/2026	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Strong-Buy
10/29/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/19/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/14/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/9/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/2/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/24/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/22/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy (B-)

(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
KMDA Kamada	$180.46M	2.57	$0.61 per share	13.31	$4.67 per share	1.73
ORGO Organogenesis	$564.17M	0.19	$0.50 per share	1.62	$0.92 per share	0.88
PRTA Prothena	$9.68M	43.42	N/A	N/A	$5.24 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
KMDA Kamada	$20.20M	$0.43	18.74	13.90	0.68	12.67%	9.36%	6.53%	N/A
ORGO Organogenesis	$37.03M	-$1.22	N/A	N/A	N/A	-39.34%	-55.28%	-23.72%	N/A
PRTA Prothena	-$244.09M	-$0.48	N/A	N/A	1.86	-45.44%	-9.98%	-9.08%	N/A

Latest ORGO, KMDA, AVTE, and PRTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	KMDA Kamada	$0.1275	$0.14	+$0.0125	$0.14	$52.51 million	$52.03 million
11/5/2026	Q3 2026	ORGO Organogenesis	-$0.1750	-$0.25	-$0.0750	-$0.2270	$52.10 million	$45.46 million
11/5/2026	Q3 2026	PRTA Prothena	-$0.2271	-$0.32	-$0.0929	-$0.32	$9.58 million	$0.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.13	1.61%	N/A	30.23%	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A

Latest ORGO, KMDA, AVTE, and PRTA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
11/9/2026	KMDA Kamada	special	$0.14		11/19/2026	11/19/2026	12/9/2026
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
KMDA Kamada	N/A	4.17	2.29
ORGO Organogenesis	0.09	3.32	2.76
PRTA Prothena	N/A	23.95	23.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
KMDA Kamada	20.38%
ORGO Organogenesis	49.57%
PRTA Prothena	97.08%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
KMDA Kamada	36.10%
ORGO Organogenesis	18.80%
PRTA Prothena	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
KMDA Kamada	462	57.51 million	36.75 million	Optionable
ORGO Organogenesis	854	129.80 million	105.40 million	Optionable
PRTA Prothena	67	51.35 million	46.01 million	Optionable

ORGO, KMDA, AVTE, and PRTA Headlines

Recent News About These Companies

Insider Buying: Prothena (NASDAQ:PRTA) Major Shareholder Buys $1,194,200.00 in Stock

November 13 at 4:09 AM | americanbankingnews.com

HC Wainwright Has Positive View of Prothena FY2026 Earnings

November 12 at 1:43 AM | americanbankingnews.com

Insider Buying: Prothena (NASDAQ:PRTA) Major Shareholder Purchases $1,194,200.00 in Stock

November 11 at 5:22 AM | insidertrades.com

Prothena (NASDAQ:PRTA) Major Shareholder Buys 140,000 Shares of Company Stock

November 10 at 3:07 PM | marketbeat.com

Wall Street Analysts See a 120.16% Upside in Prothena (PRTA): Can the Stock Really Move This High?

November 10 at 10:56 AM | zacks.com

Prothena FY2026 Earnings Forecast Increased by HC Wainwright

November 10 at 6:12 AM | marketbeat.com

Prothena (NASDAQ:PRTA) Stock Breaks Above Fifty Day Moving Average - Here's Why

November 10 at 5:19 AM | marketbeat.com

Prothena Corporation plc (NASDAQ:PRTA) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

November 7, 2026 | americanbankingnews.com

Prothena Corporation plc (NASDAQ:PRTA) Stock Has Average Target Price of $20.00

November 7, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Posts Earnings Results, Misses Expectations By $0.09 EPS

November 6, 2026 | marketbeat.com

Prothena: Q3 earnings snapshot

November 5, 2026 | msn.com

Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates

November 5, 2026 | zacks.com

Prothena Reports Third Quarter 2026 Financial Results and Business Highlights

November 5, 2026 | aol.comA

Prothena consensus price target lowered by 17.06% to $18.10

November 3, 2026 | msn.com

Prothena to Report Third Quarter 2026 Financial Results on November 5

October 30, 2026 | finance.yahoo.com

Prothena (PRTA) Projected to Release Earnings on Thursday

October 29, 2026 | marketbeat.com

Insider Buying: Prothena (NASDAQ:PRTA) Major Shareholder Acquires $403,500.00 in Stock

October 27, 2026 | insidertrades.com

Prothena (NASDAQ:PRTA) Stock: Insider William Scully Buys 50,000 Shares

October 26, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Stock: Insider William Scully Acquires 100,000 Shares

October 26, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Shares Break Below Two Hundred Day Moving Average - What's Next?

October 23, 2026 | marketbeat.com

Prothena's Partnership Strategy: Growth Driver or Limitation?

October 20, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, KMDA, AVTE, and PRTA Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$15.87 -0.67 (-4.05%)

As of 11/12/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Kamada NASDAQ:KMDA

$8.09 -0.04 (-0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$8.07 -0.02 (-0.19%)

As of 04:10 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Organogenesis NASDAQ:ORGO

$0.81 -0.15 (-16.05%)

Closing price 04:00 PM Eastern

Extended Trading

$0.81 0.00 (-0.01%)

As of 04:14 PM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Prothena NASDAQ:PRTA

$8.16 -0.07 (-0.85%)

Closing price 04:00 PM Eastern

Extended Trading

$8.16 +0.00 (+0.06%)

As of 04:15 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORGO, KMDA, AVTE, and PRTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORGO, KMDA, AVTE, and PRTA Earnings

Compare Dividends

Latest ORGO, KMDA, AVTE, and PRTA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORGO, KMDA, AVTE, and PRTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, KMDA, AVTE, and PRTA Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Kamada NASDAQ:KMDA

Organogenesis NASDAQ:ORGO

Prothena NASDAQ:PRTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORGO, KMDA, AVTE, and PRTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORGO, KMDA, AVTE, and PRTA Earnings

Compare Dividends

Latest ORGO, KMDA, AVTE, and PRTA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORGO, KMDA, AVTE, and PRTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, KMDA, AVTE, and PRTA Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Kamada NASDAQ:KMDA

Organogenesis NASDAQ:ORGO

Prothena NASDAQ:PRTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools